Noble Financial Has Positive Forecast for UNCY Q3 Earnings

Key Points

• Noble Financial raised its Q3 2026 EPS forecast for Unicycive Therapeutics to a loss of $0.23 per share from a projected loss of $0.35, while forecasting a $0.62 loss for full-year 2026 and profitability in 2027.
• Unicycive reported a Q2 loss of $0.06 per share, beating the consensus estimate of a $0.47 loss by $0.41.
• Analyst sentiment remains mixed: five analysts rate the stock Buy and two rate it Sell, producing an overall “Hold” rating and an average price target of $18.25, despite several recent target-price reductions.

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Research analysts at Noble Financial raised their Q3 2026 earnings estimates for Unicycive Therapeutics in a report released on Thursday, August 13th. Noble Financial analyst R. Leboyer now anticipates that the company will post earnings of ($0.23) per share for the quarter, up from their previous forecast of ($0.35). The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($1.17) per share. Noble Financial also issued estimates for Unicycive Therapeutics' Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at $0.64 EPS and FY2027 earnings at $3.70 EPS.

Other research analysts have also issued research reports about the company. B. Riley Financial reaffirmed a "buy" rating and set a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday. Benchmark cut their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a "speculative buy" rating on the stock in a research note on Wednesday, July 1st. Wall Street Zen upgraded Unicycive Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Guggenheim reaffirmed a "buy" rating and issued a $25.00 price target (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday. Finally, Zacks Research cut shares of Unicycive Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, July 21st. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, Unicycive Therapeutics currently has an average rating of "Hold" and an average target price of $18.25.

Unicycive Therapeutics Price Performance

Shares of UNCY opened at $5.51 on Monday. The stock has a market cap of $153.45 million, a P/E ratio of -3.15 and a beta of 1.79. The business's 50 day moving average price is $5.94 and its 200-day moving average price is $6.64. Unicycive Therapeutics has a 52 week low of $3.71 and a 52 week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.41.

Hedge Funds Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp purchased a new stake in Unicycive Therapeutics during the 2nd quarter valued at $248,000. Seven Fleet Capital Management LP purchased a new stake in shares of Unicycive Therapeutics during the first quarter valued at $367,000. Bank of America Corp DE increased its holdings in Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after buying an additional 29,378 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Unicycive Therapeutics in the 1st quarter worth about $161,000. Finally, Dimensional Fund Advisors LP purchased a new position in Unicycive Therapeutics in the 1st quarter worth about $940,000. 40.42% of the stock is owned by institutional investors.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $15 price target, substantially above the stock’s recent trading level. The firm slightly improved its FY2026 EPS forecast to a $1.43 loss from a $1.45 loss, signaling a marginally better near-term outlook.
• Positive Sentiment: Noble Financial made several favorable near-term revisions, raising its Q3 2026 forecast to a $0.23 loss from a $0.35 loss and its Q4 2026 forecast to a $0.25 loss from a $0.38 loss. Noble also improved its FY2026 forecast to a $0.62 loss from a $1.62 loss. Noble Financial Analysts Lower Earnings Estimates for UNCY
• Neutral Sentiment: Noble Financial lowered its Q1 2027 EPS estimate to $0.64 from $0.85 and its FY2027 estimate to $3.70 from $4.33, although it still projects a transition to profitability in 2027.
• Neutral Sentiment: Wall Street Zen raised Unicycive to a Hold rating, suggesting a more balanced stance on the shares. Unicycive Therapeutics Raised to Hold at Wall Street Zen
• Negative Sentiment: HC Wainwright reduced multiple forecasts, including Q3 and Q4 2026 EPS to losses of $0.40 and $0.42, respectively, and FY2027 EPS to a $1.05 loss from a $0.37 loss.
• Negative Sentiment: HC Wainwright also cut its projected long-term profitability: FY2028 EPS fell to $1.98 from $3.04, FY2029 to $3.08 from $4.57, and FY2030 to $3.11 from $5.42. These revisions imply slower earnings growth, despite the unchanged Buy rating and $15 target.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source